Two months on TRT: separating real progress from bro-science
Quick answer
The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL). The elevated hematocrit and reduced HDL they describe are expected pharmacological effects of exogenous testosterone at this exposure level, and their plan to reduce dose and donate blood aligns with Endocrine Society management guidance, though both interventions should involve a prescribing clinician. Unresolved questions include the actual hematocrit value, the current dose, and whether cardiovascular risk has been formally assessed given the lipid changes.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @doctadilf actually say?
Pretty straightforward stuff, actually. The creator reported jumping from a pre-TRT total testosterone of 590 ng/dL and free testosterone of 24 pg/mL to 1585 ng/dL total and 377 pg/mL free after two months. They felt better, which tracks. But they also flagged elevated hemoglobin and hematocrit, a drop in HDL cholesterol, and outlined a plan: more water, more cardio, blood donation, and a dose reduction. They also mentioned quitting vaping and cutting back on cannabis to help their lipid profile.
This is not your typical TRT hype video. The creator explicitly said "don't just track numbers and ego" and framed the whole thing around adjustment rather than bragging. That matters when you're evaluating what they actually claimed versus what the comment section probably wanted to hear.
Does the science back this up?
Mostly, yes. The physiology they're describing is well-documented, and their planned interventions are reasonable, if incomplete.
Elevated hematocrit is one of the most consistently observed side effects of exogenous testosterone. A 2017 review by Bachman et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that erythrocytosis (hematocrit above 54%) occurs in roughly 11-18% of men on TRT, driven by testosterone stimulating erythropoietin production. The creator's plan to donate blood is actually a clinically recognized management strategy, though it should be done in consultation with a prescribing physician, not just volunteered at a blood bank without disclosure.
The HDL drop also checks out. A 2013 meta-analysis by Corona et al. in the European Journal of Endocrinology found that testosterone therapy consistently reduces HDL cholesterol, with effect sizes varying by formulation and dose. Their plan to quit vaping and improve sleep are genuinely relevant here. Smoking and nicotine products independently suppress HDL, and sleep deprivation disrupts lipid metabolism.
What did they get wrong (or right)?
They got the biology right. Where things get murkier is the dose context and what "high" actually means for hematocrit.
The creator's total testosterone of 1585 ng/dL is above the upper limit of most laboratory reference ranges (typically 916-1000 ng/dL depending on the lab). Running supraphysiological levels isn't necessarily dangerous in the short term, but it is not "optimization" in any clinical sense. It's closer to enhancement. The creator seems to recognize this, which is why they're lowering the dose, but they don't name the number. That's a gap. Viewers watching this don't know if they're on 100 mg/week or 250 mg/week, and that context is genuinely important for anyone trying to apply this to their own situation.
On the hematocrit front, they said it's "not insane, but high." Without sharing the actual number, that's hard to evaluate. Hematocrit above 52% is where most guidelines, including those from the Endocrine Society, flag increased cardiovascular risk due to blood viscosity. Drinking more water and doing cardio help marginally. Blood donation is more meaningful. But the actual threshold matters, and omitting it is a miss.
Credit where it's due: recommending a dose reduction rather than doubling down is genuinely responsible messaging for this space.
What should you actually know?
A few things worth understanding before you interpret your own bloodwork through this lens.
First, pre-TRT total testosterone of 590 ng/dL is not low by standard clinical definitions. Most guidelines define hypogonadism below 300 ng/dL (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). That doesn't mean someone at 590 ng/dL can't have symptoms or benefit from treatment, but it does mean this is firmly in "optimization" territory, not replacement therapy in the traditional sense. That's a meaningful distinction from a risk-benefit standpoint.
Second, free testosterone of 24 pg/mL pre-TRT is actually on the higher end of normal for most adult men under 50. The creator's post-TRT free T of 377 pg/mL is well above physiological range. Free testosterone drives most of the androgenic effects, including on red blood cell production and potentially on cardiovascular markers.
Third, HDL reduction on TRT is real and the magnitude matters. A drop of 5-10% is common. A drop of 20-30% paired with other cardiovascular risk factors is a different conversation. If you're on TRT and your HDL is dropping, you need your full lipid panel reviewed by someone who can assess your actual cardiovascular risk, not just the isolated number.
Bottom line: responsible messaging, incomplete data
The creator is doing more right than wrong here. They're monitoring bloodwork, acknowledging adverse changes, and adjusting behavior. That's better than most TRT content on this platform. But the missing numbers, including the actual hematocrit value and the testosterone dose, limit how useful this is for anyone watching. "High but not insane" is not a data point. Share the number or don't make the video about the numbers.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Two months on TRT: separating real progress from bro-science, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Two months on TRT: separating real progress from bro-science is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL).
FormBlends verdict
The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL). The elevated hematocrit and reduced HDL they describe are expected pharmacological effects of exogenous testosterone at this exposure level, and their plan to reduce dose and donate blood aligns with Endocrine Society management guidance, though both interventions should involve a prescribing clinician. Unresolved questions include the actual hematocrit value, the current dose, and whether cardiovascular risk has been formally assessed given the lipid changes.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL). The elevated hematocrit and reduced HDL they describe are expected pharmacological effects of exogenous testosterone at this exposure level, and their plan to reduce dose and donate blood aligns with Endocrine Society management guidance, though both interventions should involve a prescribing clinician. Unresolved questions include the actual hematocrit value, the current dose, and whether cardiovascular risk has been formally assessed given the lipid changes.
- A pre-TRT total testosterone of 590 ng/dL does not meet the standard clinical definition of hypogonadism, which most guidelines set below 300 ng/dL (Bhasin et al., 2018, JCEM). This matters for how you frame risk versus benefit.
- Post-TRT total testosterone of 1585 ng/dL exceeds the upper physiological reference range (typically under 1000 ng/dL), placing this in enhancement territory rather than replacement, with corresponding higher risk of hematocrit elevation and lipid changes.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- A pre-TRT total testosterone of 590 ng/dL does not meet the standard clinical definition of hypogonadism, which most guidelines set below 300 ng/dL (Bhasin et al., 2018, JCEM). This matters for how you frame risk versus benefit.
- Post-TRT total testosterone of 1585 ng/dL exceeds the upper physiological reference range (typically under 1000 ng/dL), placing this in enhancement territory rather than replacement, with corresponding higher risk of hematocrit elevation and lipid changes.
- Erythrocytosis occurs in roughly 11-18% of men on TRT and is dose-dependent. Hematocrit above 52-54% raises cardiovascular risk through increased blood viscosity. The specific value matters and was not disclosed in this video.
- Therapeutic blood donation is a legitimate management strategy for TRT-related erythrocytosis, but should be disclosed to and coordinated with a prescribing clinician, not done unilaterally.
- HDL reduction on TRT is pharmacologically expected but not automatically benign. The absolute drop and baseline cardiovascular risk profile determine whether it requires active intervention beyond lifestyle changes.
- Free testosterone of 377 pg/mL post-TRT is well above the physiological range and is the fraction most responsible for androgenic effects, including red blood cell stimulation and potential lipid changes.
- Quitting nicotine products is independently beneficial for HDL regardless of TRT status. Craig et al. (1989, Arteriosclerosis) documented this relationship clearly, and it is one of the more evidence-backed lifestyle moves the creator mentioned.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dylan Clarke · TikTok creator
8.0K views on this video
2 month TRT update. The good + what I’m fixing. Optimize. Don’t ego lift your hormones. #trt #testosterone #menshealth #bloodwork #hormoneoptimization
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dylan Clarke, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.